← Back to Search

Imaging

SPECT/CT imaging following revascularization procedures for Peripheral Arterial Disease

N/A

Recruiting

Led By Albert J. Sinusas, MD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

Study Summary

This trial will use special imaging to study how well a treatment for blocked arteries works in patients with diabetes, who often have more severe disease.

Eligible Conditions

Peripheral Arterial Disease
Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ patients will be assessed prior to the revascularization procedure (baseline) and a second time 1-3 days following revascularization.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~patients will be assessed prior to the revascularization procedure (baseline) and a second time 1-3 days following revascularization.

This trial's timeline: 3 weeks for screening, Varies for treatment, and patients will be assessed prior to the revascularization procedure (baseline) and a second time 1-3 days following revascularization. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assessment of effect of percutaneous revascularization treatment measured by change in lower extremity skeletal muscle perfusion before and after treatment using quantitative SPECT/CT imaging of the lower extremities.

Assessment of lower extremity skeletal muscle perfusion in healthy control subjects compared to patients with peripheral arterial disease and diabetes using quantitative SPECT/CT imaging.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Participants with PADExperimental Treatment1 Intervention

Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.

Group II: ControlsExperimental Treatment1 Intervention

Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor

1,847 Previous Clinical Trials

2,737,528 Total Patients Enrolled

3 Trials studying Peripheral Arterial Disease

876 Patients Enrolled for Peripheral Arterial Disease

University of Illinois at Urbana-ChampaignOTHER

188 Previous Clinical Trials

37,195 Total Patients Enrolled

Albert J. Sinusas, MDPrincipal InvestigatorYale University

2 Previous Clinical Trials

67 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for patients to join this experiment?

"Affirmative. According to the clinicaltrials.gov portal, this study is actively recruiting patients who meet its requirements; it was initially posted on May 1st 2016 and recently updated on May 13th 2022. The research initiative intends to enroll 140 individuals from a single site."

Answered by AI

How many participants are engaged in this experiment?

"Affirmative, clinicaltrials.gov has information indicating that this trial is recruiting patients. It was initially posted on May 1st 2016 and modified as recently as May 13th 2022. The study aims to enrol 140 individuals from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

SPECT/CT Imaging of Skeletal Muscle Perfusion

2016. "SPECT/CT Imaging of Skeletal Muscle Perfusion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02791204.